SAB Biotherapeutics, Inc. (SABS)

NASDAQ: SABS · IEX Real-Time Price · USD
4.490
+0.270 (6.40%)
Mar 28, 2024, 10:28 AM EDT - Market open

Company Description

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies.

It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.

The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma.

In addition, its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development for the treatment or prevention of severe influenza.

Further, the company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection.

SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Sioux Falls, South Dakota.

SAB Biotherapeutics, Inc.
SAB Biotherapeutics logo
Country United States
Founded 2014
Industry Biotechnology
Sector Healthcare
Employees 56
CEO Samuel J. Reich

Contact Details

Address:
2100 East 54th Street North
Sioux Falls, South Dakota 57104
United States
Phone 605-679-6980
Website sabbiotherapeutics.com

Stock Details

Ticker Symbol SABS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001833214
CUSIP Number 78397T103
ISIN Number US78397T2024
Employer ID 85-3899721
SIC Code 2836

Key Executives

Name Position
Samuel J. Reich Chief Executive Officer and Executive Chairman
Dr. Eddie Joe Sullivan Ph.D. Co-Founder, President and Director
Christine E. Hamilton M.B.A. Co-Founder and Independent Director
Dr. Alexandra Kropotova M.B.A., M.D. Executive Vice President and Chief Medical Officer
Dr. Edward D. Hamilton D.V.M. Co-Founder and Board Observer
Michael George King Jr. Executive Vice President and Chief Financial Officer
Dr. Christoph Bausch M.B.A., Ph.D. Executive Vice President and Chief Operating Officer
Dr. Carlos N. Carillo Ph.D. Senior Vice President of Regulatory Affairs

Latest SEC Filings

Date Type Title
Mar 8, 2024 8-K Current Report
Feb 23, 2024 S-8 Securities to be offered to employees in employee benefit plans
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 2, 2024 8-K Current Report
Jan 26, 2024 8-K Current Report
Jan 26, 2024 424B5 Filing
Jan 25, 2024 8-K Current Report
Jan 19, 2024 8-K Current Report